medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2019, Número 3

<< Anterior Siguiente >>

Neumol Cir Torax 2019; 78 (3)


Estrategias actuales en el manejo de las secreciones traqueobronquiales

Cortes-Telles A, Che-Morales JL, Ortiz-Farías DL

Idioma: Español
Referencias bibliográficas: 55
Paginas: 313-323
Archivo PDF: 361.53 Kb.


RESUMEN

El aumento de la producción de moco es común en pacientes con enfermedades respiratorias, asimismo, en la población en general como resultado de la exposición a partículas irritantes e infecciones. La hipersecreción del moco en las vías respiratorias contribuye al deterioro del aclaramiento mucociliar, promueve la mucoestasis y, potencialmente, obstrucción de la vía aérea; esta acumulación continua de moco compromete el trabajo respiratorio con importante gasto energético afectando de manera negativa en la calidad de vida de las personas. Sin embargo, la investigación sobre los beneficios de las intervenciones utilizadas para controlar la hiperproducción de moco es escasa. El propósito de esta revisión es describir las diferentes medidas (farmacológicas y no farmacológicas) que existen en la actualidad para el manejo de las secreciones respiratorias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jelic S, Cunningham JA, Factor P. Clinical review: airway hygiene in the intensive care unit. Crit Care 2008;12(2):209. https://doi.org/10.1186/cc6830

  2. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest 2009;135(2):505-512. https://doi.org/10.1378/chest.08-0412

  3. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010;19(116):127-133. https://doi.org/10.1183/09059180.00003510

  4. Hess DR. Airway clearance: physiology, pharmacology, techniques, and practice. Respir Care 2007;52(10):1392-1396.

  5. 5 Lucchini A, Zanella A, Bellani G, et al. Tracheal secretion management in the mechanically ventilated patient: comparison of standard assessment and an acoustic secretion detector. Respir Care 2011;56(5):596-603. https://doi.org/10.4187/respcare.00909

  6. Rogers DF, Barnes PJ. Treatment of airway mucus hypersecretion. Ann Med 2006;38(2):116-125. https://doi.org/10.1080/07853890600585795

  7. Rubin BK. Mucolytics, expectorants, and mucokinetic medications. Respir Care 2007;52(7):859-865.

  8. Yuta A, Baraniuk JN. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep 2005;5(3):243-251.

  9. Rubin BK. An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol. Chest 1999;116(1):195-200. https://doi.org/10.1378/chest.116.1.195

  10. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996;109(2):348-352. https://doi.org/10.1378/chest.109.2.348

  11. Shim C, King M, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987;92(4):679-682. https://doi.org/10.1378/chest.92.4.679

  12. Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004;23(4):629-636.

  13. Felton VM, Borok Z, Willis BC. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 2009;297(5):L805-L812. https://doi.org/10.1152/ajplung.00009.2009

  14. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365(9470):1552-1560. https://doi.org/10.1016/S0140-6736(05)66456-2

  15. Hirai DM, Jones JH, Zelt JT, et al. Oral N-acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease. JAppl Physiol (1985) 2017;122(5):1351-1361. https://doi.org/10.1152/japplphysiol.00990.2016

  16. Ehre C, Rushton ZL, Wang B, et al. An improved inhaled mucolytic to treat airway muco-obstructive diseases. Am J Respir Crit Care Med 2019;199(2):171-180. https://doi.org/10.1164/rccm.201802-0245OC

  17. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008;153(6):752-757. https://doi.org/10.1016/j.jpeds.2008.07.011

  18. Arcuri JF, Abarshi E, Preston NJ, Brine J, Pires Di Lorenzo VA. Benefits of interventions for respiratory secretion management in adult palliative care patients-a systematic review. BMC Palliat Care 2016;15:74. https://doi.org/10.1186/s12904-016-0147-y

  19. Ha EV, Rogers DF. Novel therapies to inhibit mucus synthesis and secretion in airway hypersecretory diseases. Pharmacology 2016;97(1-2):84-100. https://doi.org/10.1159/000442794

  20. Fuloria M, Rubin BK. Evaluating the efficacy of mucoactive aerosol therapy. Respir Care 2000;45(7):868-873.

  21. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3(3):331-350.

  22. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004;125(2 Suppl):52S-60S. https://doi.org/10.1378/chest.125.2_suppl.52s

  23. Albert RK, Connett J, Bailey WC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-698. https://doi.org/10.1056/NEJMoa1104623

  24. Malerba M, Ragnoli B. Ambroxol in the 21st century: pharmacological and clinical update. Expert Opin Drug Metab Toxicol 2008;4(8):1119-1129. https://doi.org/10.1517/17425255.4.8.1119

  25. Cortes-Telles A, García-Torrentera R. Aerosoles: Fármacos y los dispositivos para su administración. Neumol Cir Torax 2013;72(2):164-174.

  26. Witek TJ Jr. The fate of inhaled drugs: the pharmacokinetics and pharmacodynamics of drugs administered by aerosol. Respir Care 2000;45(7):826-830.

  27. Colice GL. Comparing inhaled corticosteroids. Respir Care 2000;45(7):846-853.

  28. Ridling DA, Martin LD, Bratton SL. Endotracheal suctioning with or without instillation of isotonic sodium chloride solution in critically ill children. Am J Crit Care 2003;12(3):212-219.

  29. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002;109(6):693-697. https://doi.org/10.1172/JCI15218

  30. Herr C, Shaykhiev R, Bals R. The role of cathelicidin and defensins in pulmonary inflammatory diseases. Expert Opin Biol Ther 2007;7(9):1449-1461. https://doi.org/10.1517/14712598.7.9.1449

  31. Travis SM, Conway BA, Zabner J, et al. Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999;20(5):872-879.

  32. Christensen RD, Henry E, Baer VL, et al. A low-sodium solution for airway care: results of a multicenter trial. Respir Care 2010;55(12):1680-1685.

  33. Ackerman MH. The effect of saline lavage prior to suctioning. Am J Crit Care 1993;2(4):326-330.

  34. Ackerman MH, Mick DJ. Instillation of normal saline before suctioning in patients with pulmonary infections: a prospective randomized controlled trial. Am J Crit Care 1998;7(4):261-266.

  35. Li Bassi G, Zanella A, Cressoni M, Stylianou M, Kolobow T. Following tracheal intubation, mucus flow is reversed in the semirecumbent position: possible role in the pathogenesis of ventilator-associated pneumonia. Crit Care Med 2008;36(2):518-525. https://doi.org/10.1097/01.CCM.0000299741.32078.E9.

  36. American Association for Respiratory C. AARC Clinical Practice Guidelines. Endotracheal suctioning of mechanically ventilated patients with artificial airways 2010. Respir Care 2010;55(6):758-764.

  37. McCool FD, Rosen MJ. Nonpharmacologic airway clearance therapies: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):250S-259S. https://doi.org/10.1378/chest.129.1_suppl.250S.

  38. Groth S, Stafanger G, Dirksen H, Andersen JB, Falk M, Kelstrup M. Positive expiratory pressure (PEP-mask) physiotherapy improves ventilation and reduces volume of trapped gas in cystic fibrosis. Bull Eur Physiopathol Respir 1985;21(4):339-343.

  39. Oberwaldner B, Evans JC, Zach MS. Forced expirations against a variable resistance: a new chest physiotherapy method in cystic fibrosis. Pediatr Pulmonol 1986;2(6):358-367.

  40. Elkins MR, Jones A, van der Schans C. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database Syst Rev 2006;(2):CD003147. https://doi.org/10.1002/14651858.CD003147.pub3.

  41. Christensen HR, Simonsen K, Lange P, et al. PEEP-masks in patients with severe obstructive pulmonary disease: a negative report. Eur Respir J 1990;3(3):267-272.

  42. McCool FD. Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):48S-53S. https://doi.org/10.1378/chest.129.1_suppl.48S.

  43. Homnick DN. Mechanical insufflation-exsufflation for airway mucus clearance. Respir Care 2007;52(10):1296-1305.

  44. Bosch A, Winterholler M. [Technical aspects of mechanical insufflator-exsufflators. Construction and function of the Emerson CoughAssist]. Pneumologie 2008;62 Suppl 1:S49-S54. https://doi.org/10.1055/s-2007-1016441.

  45. Chatwin M, Simonds AK. The addition of mechanical insufflation/exsufflation shortens airway-clearance sessions in neuromuscular patients with chest infection. Respir Care 2009;54(11):1473-1479.

  46. Gonçalves MR, Honrado T, Winck JC, Paiva JA. Effects of mechanical insufflation-exsufflation in preventing respiratory failure after extubation: a randomized controlled trial. Crit Care 2012;16(2):R48. https://doi.org/10.1186/cc11249.

  47. Chatburn RL. High-frequency assisted airway clearance. Respir Care 2007;52(9):1224-1235.

  48. Vargas F, Bui HN, Boyer A, et al. Intrapulmonary percussive ventilation in acute exacerbations of COPD patients with mild respiratory acidosis: a randomized controlled trial [ISRCTN17802078]. Crit Care 2005;9(4):R382-R389. https://doi.org/10.1186/cc3724.

  49. Clini EM, Antoni FD, Vitacca M, et al. Intrapulmonary percussive ventilation in tracheostomized patients: a randomized controlled trial. Intensive Care Med 2006;32(12):1994-2001. https://doi.org/10.1007/s00134-006-0427-8.

  50. Arens R, Gozal D, Omlin KJ, et al. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1994;150(4):1154-1157. https://doi.org/10.1164/ajrccm.150.4.7921452.

  51. Dosman CF, Zuberbuhler PC, Tabak JI, Jones RL. Effects of positive end-expiratory pressure on oscillated volume during high frequency chest compression in children with cystic fibrosis. Can Respir J 2003;10(2):94-98. https://doi.org/10.1155/2003/792917.

  52. Yuan N, Kane P, Shelton K, Matel J, Becker BC, Moss RB. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. J Child Neurol 2010;25(7):815-821. https://doi.org/10.1177/0883073809350223.

  53. Máiz Carro L, Wagner Struwing C. [Benefits of nebulized therapy: basic concepts]. Arch Bronconeumol 2011;47 Suppl 6:2-7. https://doi.org/10.1016/S0300-2896(11)70028-X.

  54. Boe J, Dennis JH, O’Driscoll BR, et al.; European Respiratory Society Task Force on the use of nebulizers.European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001;18(1):228-242.

  55. Laube BL, Janssens HM, de Jongh FH, et al.;European Respiratory Society; International Society for Aerosols in Medicine. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011;37(6):1308-1331. https://doi.org/10.1183/09031936.00166410.




2020     |     www.medigraphic.com